Nautilus Biotechnology, Inc.
NAUT- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001808805
No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q3 2026, worth $61.0M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 28, 2026, 12:35 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 28, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Operating expenses | $66.8M | $81.5M | $76.2M | $63.6M | $50.5M |
| Research and development | $41.1M | $50.5M | $47.3M | $37.7M | $29.4M |
| Selling, general and administrative | $25.7M | $31.0M | $28.9M | $25.9M | $21.1M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.0M | -$70.8M | -$63.7M | -$57.9M | -$50.3M |
| EPS, basic | $-0.47 | $-0.56 | $-0.51 | $-0.46 | $-0.60 |
| EPS, diluted | $-0.47 | $-0.56 | $-0.51 | $-0.46 | $-0.60 |
| Weighted shares, basic | 126.3M | 125.4M | 124.9M | 124.6M | 84.5M |
| Weighted shares, diluted | 126.3M | 125.4M | 124.9M | 124.6M | 84.5M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 28, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Cash and equivalents | $12.4M | $27.6M | $19.4M | $114.5M | $185.6M |
| Total current assets | $106.0M | $132.8M | $176.8M | $187.2M | $349.2M |
| Property, plant and equipment | $3.46M | $4.08M | $4.27M | $3.70M | $2.48M |
| Total assets | $191.1M | $242.7M | $305.6M | $350.1M | $398.4M |
| Accounts payable | $943.0K | $987.0K | $1.64M | $1.27M | $1.72M |
| Total current liabilities | $7.95M | $7.63M | $9.12M | $6.79M | $5.81M |
| Total liabilities | $34.1M | $34.0M | $40.2M | $35.1M | $34.9M |
| Shareholders' equity | $157.0M | $208.7M | $265.4M | $314.9M | $363.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 28, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Operating cash flow | -$50.7M | -$59.1M | -$51.7M | -$45.8M | -$39.2M |
| Capital expenditures | $1.28M | $2.12M | $2.44M | $2.32M | $2.27M |
| Free cash flow | -$52.0M | -$61.3M | -$54.2M | -$48.1M | -$41.5M |
| Stock-based compensation | $6.84M | $12.7M | $12.1M | $10.4M | $7.93M |
| Investing cash flow | $35.2M | $66.3M | -$43.7M | -$25.7M | -$139.0M |
| Financing cash flow | $214.0K | $1.14M | $368.0K | $562.0K | $327.4M |
| Net change in cash | -$15.3M | $8.25M | -$95.1M | -$71.0M | $149.2M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 22, 2026 | 127.4M | +0.8% | SEC |
| Jul 24, 2026 | 127.3M | +0.8% | SEC |
| Apr 23, 2026 | 127.1M | +0.7% | SEC |
| Feb 19, 2026 | 126.6M | +0.3% | SEC |
| Oct 23, 2025 | 126.3M | +0.6% | SEC |
| Jul 25, 2025 | 126.3M | +0.7% | SEC |
| Apr 24, 2025 | 126.1M | +0.7% | SEC |
| Feb 21, 2025 | 126.1M | +0.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.